Condition: Gastric Cancer · Chemotherapy-induced Peripheral Neuropathy · Paclitaxel · Sponsor: City of Hope Medical Center
Although advances in chemotherapy have improved the prognosis of gastric cancer patients, many patients still suffer from adverse events. Therefore, it is necessary to establish personalized treatment by identifying patients at high risk for side effects. Although paclitaxel-based therapy is the standard second-line treatment, peripheral neuropathy is a troublesome adverse event. The purpose of this study is to establish a liquid biopsy assay to predict paclitaxel-induced peripheral neuropathy in gastric cancer patients.
This description comes directly from the study's public registry record.
Ajay Goel, PhD · 6262183452 · AJGOEL@COH.ORG
Koichi Takiguchi, PhD · 6262183452 · ktakiguchi@coh.org
Always discuss trial participation with your own doctor first.
| Kawasaki Medical University | Kurashiki, Okayama-ken, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06490159